8-K: Healthpeak Q3 2025: Strategic Sales, Lab Recovery, CCRC Growth

Healthpeak Properties reported third-quarter 2025 results, highlighting strong outpatient medical and CCRC performance, strategic asset sales, and an anticipated inflection point in the biopharma sector, despite a revised full-year earnings per share outlook.

Summary

• Reported a net loss of $(0.17) per share for the third quarter of 2025, compared to net income of $0.12 per share in Q3 2024.
• Diluted Nareit FFO was $0.45 per share for Q3 2025, an increase from $0.44 per share in Q3 2024.
• Diluted FFO as Adjusted was $0.46 per share for Q3 2025, up from $0.45 per share in Q3 2024.
• Diluted AFFO remained flat at $0.42 per share for Q3 2025 compared to Q3 2024.
• Total Merger-Combined Same-Store Cash (Adjusted) NOI growth was 0.9% for Q3 2025 and 3.8% year-to-date.
• Outpatient Medical segment achieved +5.4% cash re-leasing spreads on renewals and saw total occupancy increase by +10 basis points sequentially.
• CCRC Merger-Combined Same-Store Cash (Adjusted) NOI grew by 9.4% in Q3 2025, with year-to-date growth at 11.3%, and total occupancy increased by +70 basis points sequentially.
• Year-to-date non-refundable entry fee cash collections for CCRCs totaled $108 million, a 13% increase over the same period last year.
• Executed new and renewal leases totaling 1.5 million square feet in Q3 2025, including 1.2 million square feet in Outpatient Medical and 339,000 square feet in Lab.
• Issued $500 million of 4.75% senior unsecured notes due 2033 in August 2025.
• Net Debt to Adjusted EBITDAre stood at 5.3x for the quarter ended September 30, 2025.
• Available liquidity was approximately $2.7 billion as of October 23, 2025.
• Reaffirmed full-year 2025 guidance for Diluted Nareit FFO per share ($1.78 $1.84), Diluted FFO as Adjusted per share ($1.81 $1.87), and Total Merger-Combined Same-Store Cash (Adjusted) NOI growth (3.0% 4.0%).
• Updated full-year 2025 guidance for Diluted earnings per common share from $0.25 $0.31 to $0.00 $0.06.

Sentiment

Score: 6

Explanation: The sentiment is mixed. Strong operational performance in outpatient medical and CCRC segments, strategic asset sales, and positive biopharma sector sentiment are favorable. However, the reported net loss and the significant downward revision of full-year diluted EPS guidance introduce notable concerns and uncertainty.

Positives

• Outpatient medical demand is growing faster than new supply, driving strong cash re-leasing spreads of +5.4% on renewals and higher annual escalators of +3% on new leases.
• Total occupancy in the outpatient medical segment increased by +10 basis points sequentially.
• Private market values for outpatient medical buildings have strengthened due to declining inflation and interest rates.
• The merger with Physicians Realty Trust has proven timely and highly successful, benefiting from strengthening market prices.
• The CCRC portfolio's NOI is up more than +50% since 2019, with year-to-date same-store growth of +11% over the prior year, and total occupancy increased by +70 basis points sequentially.
• Year-to-date non-refundable entry fee cash collections for CCRCs increased by 13% compared to the same period last year.
• A palpable shift in sentiment across the biopharma sector is observed, driven by M&A activity, clinical data readouts, lower interest rates, and reduced regulatory uncertainty, leading to a pickup in leasing activity and the highest pipeline since Q2 2024.
• Early rollout of technology innovation initiatives has improved company-wide connectivity, data access, and productivity, contributing to a 5% reduction in G&A guidance this year.
• Maintained a strong balance sheet with 5.3x Net Debt to Adjusted EBITDAre and a well-covered dividend with a 71% AFFO payout ratio year-to-date.
• Successfully issued $500 million of 4.75% senior unsecured notes due 2033 at a 92 basis point spread over the reference U.S. Treasury bond, representing the lowest 7-year spread of any BBB+/Baa1 rated REIT year-to-date.

Negatives

• Reported a net loss of $(0.17) per share for Q3 2025, a significant decline from net income of $0.12 per share in Q3 2024.
• Full-year 2025 diluted earnings per common share guidance was updated downwards from $0.25 $0.31 to $0.00 $0.06.
• The Lab segment experienced a (3.2%) year-over-year Merger-Combined Same-Store Cash (Adjusted) NOI growth in Q3 2025.
• Expect near-term Lab occupancy to decline due to expirations and early terminations, despite an improved sentiment in the biopharma sector.
• The net loss for Q3 2025 and YTD 2025 was significantly impacted by other-than-temporary impairment charges on certain unconsolidated real estate joint ventures.

Risks

• Macroeconomic trends may increase construction, labor, and other operating costs.
• Changes within the life science industry, significant regulation, funding requirements, and uncertainty faced by lab tenants could adversely impact performance.
• Factors adversely affecting tenants, operators, or borrowers' ability to meet financial and contractual obligations.
• The insolvency or bankruptcy of one or more major tenants, operators, or borrowers.
• Concentration of real estate investments in the healthcare property sector makes the company vulnerable to downturns in that specific sector.
• Illiquidity of real estate investments.
• Ability to identify and secure new or replacement tenants and operators.
• Property development, redevelopment, and tenant improvement risks can render projects less profitable or unprofitable and delay or prevent completion.
• The ability of hospitals on whose campuses outpatient medical buildings are located, and their affiliated healthcare systems, to remain competitive or financially viable.
• Operational risks associated with senior housing properties managed by third parties.
• Economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas with concentrated investments.
• Uninsured or underinsured losses could result in significant capital loss, lower revenues, and unanticipated expenses.
• Use of joint ventures may limit returns and flexibility with jointly owned investments.
• Competition for suitable healthcare properties to grow the investment portfolio.
• Any requirement to recognize reserves, allowances, credit losses, or impairment charges.
• Investment of substantial resources and time in transactions that are not consummated.
• Ability to successfully integrate and/or operate acquisitions or internalize property management.
• Potential impact of unfavorable resolution of litigation or disputes and resulting rising liability and insurance costs.
• Environmental compliance costs and liabilities associated with real estate investments.
• Human capital risks, including the loss or limited availability of key personnel.
• Reliance on information technology and any material failure, inadequacy, interruption, or security failure of that technology.
• Volatility, disruption, or uncertainty in the financial markets.
• Increased borrowing costs, which could impact the ability to refinance existing debt, sell properties, and conduct investment activities.
• Availability of external capital on acceptable terms or at all.
• An increase in the level of indebtedness and covenants in debt instruments that may limit operational flexibility.
• Volatility in the market price and trading volume of common stock and adverse changes in credit ratings.
• Failure of tenants, operators, and borrowers to comply with federal, state, and local laws and regulations.
• Changes to U.S. federal income tax laws and potential deferred and contingent tax liabilities from corporate acquisitions.

Future Outlook

Management reaffirmed full-year 2025 guidance for Diluted Nareit FFO per share at $1.78 $1.84, Diluted FFO as Adjusted per share at $1.81 $1.87, and Total Merger-Combined Same-Store Cash (Adjusted) NOI growth at 3.0% 4.0%. However, the guidance for Diluted earnings per common share was updated downwards from $0.25 $0.31 to $0.00 $0.06. The company expects near-term Lab occupancy to decline due to expirations and early terminations, but recent trends suggest the underlying biopharma sector may be approaching an inflection point. Opportunistic sales and recapitalizations are expected to generate $1 billion or more in proceeds, which will be used to strengthen the balance sheet, recycle capital into new outpatient medical developments, acquire distressed lab properties, and/or repurchase shares.

Management Comments

• Outpatient medical demand is growing faster than new supply, which, combined with our leading platform and deep health system relationships, is driving strong cash re-leasing spreads.
• Our merger with Physicians Realty Trust has proven timely, as we have benefited from these strengthening prices, and our merger integration is complete and highly successful.
• We believe there has been a palpable shift in sentiment across the biopharma sector since the start of the school year, driven by M&A activity, clinical data readouts, lower interest rates, reduced regulatory uncertainty, and biopharma stock price performance.
• Our pipeline is at its highest level since Q2 2024, and with a higher allocation toward new leasing.
• Our strong balance sheet (5.3x debt/EBITDA) and well-covered dividend (71% AFFO payout ratio year-to-date) remain key strengths of the platform, allowing us to deploy capital opportunistically.

Industry Context

The company's performance reflects broader industry trends, including growing demand in the outpatient medical sector and strengthening private market values for medical buildings, likely influenced by declining inflation and interest rates. The observed shift in sentiment within the biopharma sector, driven by M&A, clinical data, and reduced regulatory uncertainty, suggests a potential recovery for the lab real estate market, aligning with the company's strategic focus on this segment. The continued strong performance of the CCRC portfolio indicates resilience and demand in the senior housing market.

Comparison to Industry Standards

• The issuance of $500 million of 4.75% senior unsecured notes due 2033 at a 92 basis point spread over the reference U.S. Treasury bond represents the lowest 7-year spread of any BBB+/Baa1 rated REIT year-to-date, indicating strong market confidence in the company's credit profile compared to peers with similar credit ratings.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Will be impacted by the net loss and lowered EPS guidance, but also by the continued dividend payments, potential share repurchases, and strategic asset recycling aimed at long-term value creation.
• Employees: Management changes indicate a strategic focus on key growth areas, potentially creating new opportunities and roles.
• Customers/Tenants: Strong re-leasing spreads and occupancy growth in outpatient medical suggest stable demand, while anticipated recovery in the biopharma sector could benefit lab tenants.
• Creditors: The strong balance sheet, successful debt issuance at favorable terms, and available liquidity reinforce the company's ability to meet its financial obligations.
• Investment Professionals: The mixed financial results, strategic initiatives, and updated guidance provide critical data for valuation and investment decisions.

Next Steps

• Opportunistic sales and recapitalizations of $1 billion or more are in various stages of negotiation, with proceeds to be used for balance sheet strengthening, new outpatient medical developments, distressed lab property acquisitions, and/or share repurchases.
• Additional asset sales totaling $204 million are under contract and expected to close in the fourth quarter.
• The sale of a four-building lab campus in Salt Lake City, Utah, for $68 million is expected to close in January 2026.
• A conference call and webcast are scheduled for October 24, 2025, to discuss the results.

Key Dates

Recommendation

The company presents a mixed financial picture. While operational performance in outpatient medical and CCRC segments remains strong, with positive re-leasing spreads and NOI growth, the reported net loss for Q3 2025 and the significant downward revision of full-year diluted EPS guidance are concerning. Strategic initiatives, including opportunistic asset sales and a positive shift in biopharma sentiment, offer potential upside. The balance sheet remains robust with ample liquidity and a well-covered dividend. However, the near-term uncertainty from the net loss and lowered earnings outlook, coupled with expected near-term lab occupancy declines, suggests a 'hold' recommendation. Investors should monitor the execution of strategic sales, the recovery in the lab sector, and future earnings reports for clearer directional signals.

Keywords

Healthcare REIT, Real Estate Investment Trust, Medical Office Buildings, Life Science Real Estate, Lab Properties, Continuing Care Retirement Communities, Senior Housing, Q3 2025 Results, Financial Performance, Asset Dispositions, Leasing Activity, Balance Sheet, Corporate Governance, Biopharma Sector